ReviewPLoS neglected tropical diseases2015
The Complexity of a Dengue Vaccine: A Review of the Human Antibody Response.
Review in PLoS neglected tropical diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 107 citations in OpenAlex.
- mRNA-LNP Vaccines Encoding for Dengue Optimized prM/ENV Proteins Induce Protective Immunity without ADE.bioRxiv : the preprint server for biology · 2025Article
- Antiviral activity of myricetin glycosylated compounds isolated fromEXCLI journal · 2023Article
- In Silico Comparative Analysis of Predicted B Cell Epitopes against Dengue Virus (Serotypes 1-4) Isolated from the Philippines.Vaccines · 2022Article
- Zika virus-like particle vaccine fusion loop mutation increases production yield but fails to protect AG129 mice against Zika virus challenge.PLoS neglected tropical diseases · 2022Article
- DENV-Mimetic Polymersome Nanoparticles Bearing Multi-Epitope Lipopeptides Antigen as the Next-Generation Dengue Vaccine.Pharmaceutics · 2022Article
- A Novel Orf Virus D1701-VrV-Based Dengue Virus (DENV) Vaccine Candidate Expressing HLA-Specific T Cell Epitopes: A Proof-of-Concept Study.Biomedicines · 2021Article
- Optimization of 4-Anilinoquinolines as Dengue Virus Inhibitors.Molecules (Basel, Switzerland) · 2021Article
- Dengue Virus Serotype 1 Conformational Dynamics Confers Virus Strain-Dependent Patterns of Neutralization by Polyclonal Sera.Journal of virology · 2021Article
- Refocusing the Immune Response to Selected Epitopes on a Zika Virus Protein Antigen by Nanopatterning.Advanced healthcare materials · 2021Article
- ApoA1 Neutralizes Proinflammatory Effects of Dengue Virus NS1 Protein and Modulates Viral Immune Evasion.Journal of virology · 2021Article
- Intradermal Delivery of Dendritic Cell-Targeting Chimeric mAbs Genetically Fused to Type 2 Dengue Virus Nonstructural Protein 1.Vaccines · 2020Article
- Anti-Flavivirus Vaccines: Review of the Present Situation and Perspectives of Subunit Vaccines Produced inVaccines · 2020Review
- Variation in the microbiota across different developmental stages of Aedes albopictus is affected by ampicillin exposure.MicrobiologyOpen · 2020Article
- Identification of Dengue Virus Serotype 3 Specific Antigenic Sites Targeted by Neutralizing Human Antibodies.Cell host & microbe · 2020Article
- Cross-Reactive Antibodies during Zika Virus Infection: Protection, Pathogenesis, and Placental Seeding.Cell host & microbe · 2020Review
- Two Is Better Than One: Evidence for T-Cell Cross-Protection Between Dengue and Zika and Implications on Vaccine Design.Frontiers in immunology · 2020Review
- Oligomeric state of the ZIKV E protein defines protective immune responses.Nature communications · 2019Article
- Article
- Dengue type 1 viruses circulating in humans are highly infectious and poorly neutralized by human antibodies.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dengue is the most prevalent mosquito-borne viral disease worldwide. Yet, there are no vaccines or specific antivirals available to prevent or treat the disease. Several dengue vaccines are currently in clinical or preclinical stages. The most advanced vaccine is the chimeric tetravalent CYD-TDV vaccine of Sanofi Pasteur. This vaccine has recently cleared Phase III, and efficacy results have been published. Excellent tetravalent seroconversion was seen, yet the protective efficacy against infection was surprisingly low. Here, we will describe the complicating factors involved in the generation of a safe and efficacious dengue vaccine. Furthermore, we will discuss the human antibody responses during infection, including the epitopes targeted in humans. Also, we will discuss the current understanding of the assays used to evaluate antibody response. We hope this review will aid future dengue vaccine development as well as fundamental research related to the phenomenon of antibody-dependent enhancement of dengue virus infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.